Jeremy G. Chadwick, Chief Operating Officer at Kymera Therapeutics, Inc. (KYMR), sold 22,240 shares at $85.38 ($1.9M) on 2026-03-31, disclosed to the SEC on 2026-04-01.
Scheduled sale ($1.9M) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $85.38 | 7,600 | $649K | 34.2% |
| 2 | $85.41 | 13,540 | $1.2M | 60.9% |
| 3 | $86.05 | 1,100 | $95K | 5.0% |
| Total | $85.43 avg | 22,240 | $1.9M | 100% |
| Filing → |
| KYMR | SELL | 2026-04-16 | $590K | — | Filing → |
| KYMR | SELL | 2026-03-25 | $18.0M | — | Filing → |
| KYMR | SELL | 2026-03-11 | $4.3M | — | Filing → |